Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first half

July 7, 2026 10:54 AM EDTUpdated 15 hours ago DealsPharma No­var­tis, Ver­tex and Ipsen ex­tend phar­ma's M&A spree af­ter 45 first-half ac­qui­si­tions Kyle LaHucik Biotech Correspondent Bio­phar­ma’s M&A en­gine is revved up and shows no signs of cool­ing off. Four com­pa­nies have an­nounced ac­qui­si­tions in the first six days of Ju­ly … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER